TELA Bio (TELA) Capital Expenditures Growth (1y) (2019 - 2026)
TELA Bio (TELA) Capital Expenditures Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.36 Bn | 175.06 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.86 Bn | 125.99 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.02 Bn | 98.80 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.21 Bn | 66.76 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | -11.95% |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | 106.98% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 24.11 Bn | 20.99 Bn | 2.07 Bn | -47.73% |
| 10 | TELA Bio | 38.25 Mn | -1.29 Mn | 12.52 Mn | 271.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 271.88% |
| Dec 31, 2025 | -88.82% |
| Sep 30, 2025 | 75.83% |
| Jun 30, 2025 | 194.21% |
| Mar 31, 2025 | -81.82% |
| Dec 31, 2024 | 383.62% |
| Sep 30, 2024 | -66.39% |
| Jun 30, 2024 | -83.33% |
| Mar 31, 2024 | 53.04% |
| Dec 31, 2023 | 64.96% |
| Sep 30, 2023 | -47.50% |
| Jun 30, 2023 | 65.26% |
| Mar 31, 2023 | -65.77% |
| Dec 31, 2022 | -1,286.96% |
| Sep 30, 2022 | 1,260.00% |
| Jun 30, 2022 | -860.00% |
| Mar 31, 2022 | 1,427.27% |
| Dec 31, 2021 | 154.76% |
| Sep 30, 2021 | 51.52% |
| Jun 30, 2021 | -10.71% |